Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
HCC1806
TNBC
Basal A
Cetuximab
EGFR
ErbB
7830.018
uM
inf
inf
0.8437 0.8437 0.0000 -0.0352
0.4991
1.5320
HCC1806
TNBC
Basal A
Cetuximab
EGFR
ErbB
9376.026
uM
inf
0.00355
0.6382 0.6973 1.1036 0.0999
0.9151
1.6827
HCC1806
TNBC
Basal A
Cetuximab
EGFR
ErbB
7829.042
uM
inf
0.00429
0.6767 0.7343 5.0000 0.1048
0.9467
1.8673
MCF 10F
NM
-
Trastuzumab
HER2
ErbB
7487.102
uM
5.78510
28.60730
0.4084 -1.0000 0.6873 0.0988
0.8554
1.5273
SUM185PE
TNBC
Luminal
Cetuximab
EGFR
ErbB
7921.042
uM
inf
inf
1.0399 1.0399 0.0000 -0.0494
-236.5755
0.6355
SUM185PE
TNBC
Luminal
Cetuximab
EGFR
ErbB
10146.124
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.9296
HCC70
TNBC
Basal A
Cetuximab
EGFR
ErbB
9501.026
uM
inf
0.01283
0.4925 0.5840 1.2619 0.0978
0.8957
0.7616
MCF7
HR+
Luminal
Cetuximab
EGFR
ErbB
7874.018
uM
inf
inf
0.9611 0.9611 0.0000 -0.0261
-0.1994
1.6506
MCF 10A
NM
Basal B
Trastuzumab
HER2
ErbB
9551.026
uM
inf
inf
0.9124 0.9124 0.0000 -0.0111
0.4645
2.6508
MCF7
HR+
Luminal
Cetuximab
EGFR
ErbB
7875.018
uM
inf
inf
0.9316 0.9316 0.0000 -0.0136
0.3967
1.6565
MDA-MB-436
TNBC
Basal B
Cetuximab
EGFR
ErbB
7902.018
uM
inf
inf
1.0500 1.0500 0.0000 -0.0247
-0.1948
1.8686
MCF 10F
NM
-
Cetuximab
EGFR
ErbB
7871.018
uM
inf
inf
0.9011 0.9011 0.0000 -0.0407
-0.0154
1.1973
MDA-MB-436
TNBC
Basal B
Cetuximab
EGFR
ErbB
7898.018
uM
inf
inf
0.9583 0.9583 0.0000 -0.0243
-0.0431
1.1279
MDA-MB-436
TNBC
Basal B
Cetuximab
EGFR
ErbB
7900.018
uM
inf
inf
0.5694 0.5694 0.0000 0.2033
-0.0548
0.8304
MCF 10A
NM
Basal B
Cetuximab
EGFR
ErbB
7867.042
uM
0.82087
0.24212
0.5210 0.3793 1.1638 0.0459
0.9580
2.3427
HCC1806
TNBC
Basal A
Trastuzumab
HER2
ErbB
9376.026
uM
inf
inf
0.9395 0.9395 0.0000 -0.0232
0.0979
1.6827
MDA-MB-175-VII
HR+
Luminal
Cetuximab
EGFR
ErbB
7884.018
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.6074
SUM159PT
TNBC
Basal B
Cetuximab
EGFR
ErbB
7920.018
uM
inf
inf
0.9492 0.9492 0.0000 0.0108
0.4781
4.3723
HCC38
TNBC
Basal B
Cetuximab
EGFR
ErbB
10268.122
uM
0.92849
0.80222
0.7620 0.2528 4.8199 -0.0144
0.6866
0.6345
MDA-MB-436
TNBC
Basal B
Cetuximab
EGFR
ErbB
7899.018
uM
inf
inf
0.8519 0.8519 0.0000 0.0052
0.3918
2.0432
HBL-100
Unknown
Unknown
Pertuzumab
7429.102
mg/ml
inf
0.21142
0.9391 0.9176 0.6095 0.0085
0.7039
2.4347
HCC70
TNBC
Basal A
Cetuximab
EGFR
ErbB
7860.042
uM
1.41750
6.04060
0.6742 -0.9996 0.7577 0.0164
0.8799
0.6736
HCC1937
TNBC
Basal A
Cetuximab
EGFR
ErbB
7832.042
uM
0.57736
1.87360
0.4323 -1.0000 0.9333 0.0778
0.8653
1.2810
LY2
HR+
Luminal
Cetuximab
EGFR
ErbB
7865.018
uM
inf
inf
-0.1870 -0.1870 0.0000 0.5240
-0.0010
1.1920
LY2
HR+
Luminal
Cetuximab
EGFR
ErbB
9536.006
uM
inf
inf
0.9716 0.9716 0.0000 0.0671
0.1220
1.2564